|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7070782B1
(en)
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6569432B1
(en)
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
EP0812356B1
(en)
|
1995-02-24 |
2006-02-08 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6150508A
(en)
*
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6207805B1
(en)
*
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
|
GB2328871A
(en)
*
|
1997-09-05 |
1999-03-10 |
Merck & Co Inc |
Compositions for inhibiting platelet aggregation
|
|
WO1999043710A1
(en)
*
|
1998-02-26 |
1999-09-02 |
Beckman Coulter, Inc. |
Prostate-specific membrane antigens and methods of making and using
|
|
EP2080802B1
(en)
*
|
1998-06-01 |
2017-03-29 |
Agensys, Inc. |
Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
|
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
|
SE9900495D0
(sv)
*
|
1999-02-12 |
1999-02-12 |
Pharmatrix Ab |
Vaccine composition
|
|
WO2000050457A1
(en)
*
|
1999-02-22 |
2000-08-31 |
Beckman Coulter, Inc. |
Prostate-specific membrane antigens and methods of making and using
|
|
EP1710256A1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
DE60031279T2
(de)
*
|
1999-07-29 |
2007-05-16 |
Medarex, Inc. |
Humane monoklonale antikörper gegen prostata spezifisches membranantigen
|
|
FR2797743B1
(fr)
*
|
1999-08-23 |
2003-08-08 |
Urogene |
Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
|
|
EP1221053A4
(en)
*
|
1999-09-13 |
2004-12-22 |
Neil H Bander |
METHOD FOR INSULATING PROSTATIC EPITHELIC CELLS FROM SPERM
|
|
JP4838436B2
(ja)
*
|
2001-04-04 |
2011-12-14 |
積水メディカル株式会社 |
抗ヒト肝性トリグリセリドリパーゼ抗体
|
|
ATE535258T1
(de)
|
2001-06-01 |
2011-12-15 |
Cornell Res Foundation Inc |
Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
|
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
JP2005527474A
(ja)
|
2001-09-20 |
2005-09-15 |
コーネル リサーチ ファンデーション インコーポレーテッド |
前立腺特異的膜抗原に特異的な結合剤を用いて、皮膚障害を治療するかまたは防止するための方法および組成物
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
US20040161776A1
(en)
*
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
|
ES2559002T3
(es)
|
2001-10-23 |
2016-02-10 |
Psma Development Company, L.L.C. |
Anticuerpos contra PSMA
|
|
DE60323677D1
(de)
|
2003-01-10 |
2008-10-30 |
Millennium Pharm Inc |
Verfahren zur bestimmung des wiederauftretens von prostata krebs
|
|
WO2006089231A2
(en)
|
2005-02-18 |
2006-08-24 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
|
EP3300739A3
(en)
*
|
2005-03-31 |
2018-07-18 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
KR20080056167A
(ko)
|
2005-09-26 |
2008-06-20 |
메다렉스, 인코포레이티드 |
씨디70에 대한 인간 모노크로날 항체
|
|
JP2009531324A
(ja)
|
2006-03-20 |
2009-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
|
|
WO2009032949A2
(en)
|
2007-09-04 |
2009-03-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
|
EP2255188B1
(en)
*
|
2008-02-29 |
2016-08-24 |
Imec |
Biosensor for the detection of neurotransmitters
|
|
WO2010027513A2
(en)
|
2008-09-08 |
2010-03-11 |
Psma Development Company, Llc |
Methods for killing psma-expressing, taxane-resistant cancer cells
|
|
WO2010096486A1
(en)
|
2009-02-17 |
2010-08-26 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
EP2506876B1
(en)
|
2009-12-02 |
2016-10-12 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
AU2012244673A1
(en)
|
2011-04-21 |
2013-11-28 |
Seattle Genetics, Inc. |
Novel binder-drug conjugates (ADCs) and their use
|
|
RU2632647C2
(ru)
|
2011-04-22 |
2017-10-06 |
Аптево Рисерч Энд Девелопмент Ллс |
Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
|
|
CN106163568B
(zh)
|
2013-12-23 |
2021-03-23 |
拜耳制药股份公司 |
含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
|
|
EP3310440A1
(de)
|
2015-06-22 |
2018-04-25 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
MX2018003292A
(es)
|
2015-09-21 |
2018-08-01 |
Aptevo Res & Development Llc |
Polipéptidos de unión a cd3.
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
JP7251981B2
(ja)
|
2016-03-24 |
2023-04-04 |
バイエル ファーマ アクチエンゲゼルシャフト |
酵素開裂基を有する細胞毒性活性剤のプロドラッグ
|
|
JP7022707B2
(ja)
|
2016-06-15 |
2022-02-18 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
|
|
PE20191235A1
(es)
|
2016-12-21 |
2019-09-11 |
Bayer Pharma AG |
Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
|
|
US12059472B2
(en)
|
2016-12-21 |
2024-08-13 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
EP3558387B1
(de)
|
2016-12-21 |
2021-10-20 |
Bayer Pharma Aktiengesellschaft |
Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
|
|
CN112119157B
(zh)
|
2018-03-06 |
2025-01-14 |
宾夕法尼亚大学董事会 |
前列腺特异性膜抗原car及其使用方法
|
|
EP3806904A4
(en)
|
2018-06-18 |
2022-04-27 |
Eureka Therapeutics, Inc. |
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED CONSTRUCTS AND USES THEREOF
|
|
HUE061078T2
(hu)
|
2018-07-31 |
2023-05-28 |
Heidelberg Pharma Res Gmbh |
PSMA elleni humanizált ellenanyagok
|